 |
|
Association of Low Plasma Aβ42/Aβ40 Ratios With Increased Imminent Risk for Mild Cognitive Impairment and Alzheimer Disease
Neill R. Graff-Radford, MBBCh, FRCP;
Julia E. Crook, PhD;
John Lucas, PhD;
Bradley F. Boeve, MD;
David S. Knopman, MD;
Robert J. Ivnik, PhD;
Glenn E. Smith, PhD;
Linda H. Younkin, PhD;
Ronald C. Petersen, MD, PhD;
Steven G. Younkin, MD, PhD
Arch Neurol. 2007;64(3):354-362.
Background To develop preventive therapy for Alzheimer disease (AD), it is essential to develop AD-related biomarkers that identify at-risk individuals in the same way that cholesterol levels identify persons at risk for heart disease.
Objective To determine whether plasma levels of amyloid β protein (Aβ40 and Aβ42) are useful for identifying cognitively normal elderly white subjects at increased risk for mild cognitive impairment (MCI) and AD.
Design Using well-established sandwich enzyme-linked immunosorbent assays, plasma Aβ40 and Aβ42 levels were analyzed at baseline in a prospective, elderly white cohort followed up for 2 to 12 (median, 3.7) years to detect incident cases of MCI or AD.
Setting Cognitively normal, community-based white volunteers recruited from primary care settings into the Mayo Rochester Alzheimer Disease Patient Registry.
Patients We followed up 563 cognitively normal white volunteers (median age, 78 years; 62% female) who had at least 1 follow-up visit after measurement of baseline plasma Aβ levels.
Main Outcome Measures The primary outcome was time to development of MCI or AD. The secondary outcome was the annualized rate of cognitive change in patients for whom we had 2 Mattis Dementia Rating Scale evaluations 3 to 7 years apart.
Results During follow-up, 53 subjects developed MCI or AD. Subjects with plasma Aβ42/Aβ40 ratios in the lower quartiles showed significantly greater risk of MCI or AD (P = .04, adjusted for age and apolipoprotein E genotype). Comparison of subjects with plasma Aβ42/Aβ40 ratios in the lowest vs the highest quartile gave a relative risk of 3.1 (95% confidence interval, 1.1-8.3). After adjusting for age and apolipoprotein E genotype, regression analysis using annualized changes in the Dementia Rating Scale scores as an outcome variable showed that participants with lower Aβ42/Aβ40 ratios had greater cognitive decline (P = .02).
Conclusion The plasma Aβ42/Aβ40 ratio may be a useful premorbid biomarker for identifying cognitively normal elderly white subjects who are at increased risk for developing MCI or AD.
Author Affiliations: Departments of Neurology (Dr Graff-Radford), Biostatistics (Dr Crook), Psychiatry and Psychology (Dr Lucas), and Neuroscience (Drs L. H. Younkin and S. G. Younkin), Mayo Clinic, Jacksonville, Fla; and Departments of Neurology (Drs Boeve, Knopman, and Petersen) and Psychiatry and Psychology (Drs Ivnik and Smith), Mayo Clinic, Rochester, Minn.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Plasma Amyloid beta(42) and Amyloid beta(40) Levels Are Associated With Early Cognitive Dysfunction After Cardiac Surgery.
Evered et al.
Ann. Thorac. Surg. 2009;88:1426-1432.
ABSTRACT
| FULL TEXT
Invited commentary.
Hogue
Ann. Thorac. Surg. 2009;88:1432-1432.
FULL TEXT
Ten-Year Change in Plasma Amyloid {beta} Levels and Late-Life Cognitive Decline
Okereke et al.
Arch Neurol 2009;66:1247-1253.
ABSTRACT
| FULL TEXT
Plasma {beta}-Amyloid 1-40 Is Associated With the Diffuse Small Vessel Disease Subtype
Gomis et al.
Stroke 2009;40:3197-3201.
ABSTRACT
| FULL TEXT
Association of plasma amyloid {beta} with risk of dementia: The prospective Three-City Study
Lambert et al.
Neurology 2009;73:847-853.
ABSTRACT
| FULL TEXT
A Specific Enzyme-Linked Immunosorbent Assay for Measuring {beta}-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer Disease
Xia et al.
Arch Neurol 2009;66:190-199.
ABSTRACT
| FULL TEXT
Plasma A{beta}, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial
Viswanathan et al.
Neurology 2009;72:268-272.
ABSTRACT
| FULL TEXT
Peripheral A{beta} subspecies as risk biomarkers of Alzheimer's disease
Schupf et al.
Proc. Natl. Acad. Sci. USA 2008;105:14052-14057.
ABSTRACT
| FULL TEXT
Detecting Alzheimer disease before it happens: The key to prevention?
Quinn and Sabbagh
Neurology 2008;71:78-79.
FULL TEXT
Biochemical markers in persons with preclinical familial Alzheimer disease
Ringman et al.
Neurology 2008;71:85-92.
ABSTRACT
| FULL TEXT
The Clinical Significance of Plasmatic Amyloid A{beta}-40 Peptide Levels in Alzheimer's Disease Patients Treated With Galantamine
Modrego et al.
AM J ALZHEIMERS DIS OTHER DEMEN 2008;23:286-290.
ABSTRACT
Plasma Amyloid {beta}-Protein and C-reactive Protein in Relation to the Rate of Progression of Alzheimer Disease
Locascio et al.
Arch Neurol 2008;65:776-785.
ABSTRACT
| FULL TEXT
Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study
Lopez et al.
Neurology 2008;70:1664-1671.
ABSTRACT
| FULL TEXT
Amyloid-Associated Depression: A Prodromal Depression of Alzheimer Disease?
Sun et al.
Arch Gen Psychiatry 2008;65:542-550.
ABSTRACT
| FULL TEXT
Toward a plasma marker for Alzheimer disease: Some progress, but still a long way to go
Crystal and Davies
Neurology 2008;70:586-587.
FULL TEXT
Plasma amyloid {beta} protein is elevated in late-onset Alzheimer disease families
Ertekin-Taner et al.
Neurology 2008;70:596-606.
ABSTRACT
| FULL TEXT
Plasma {beta} Amyloid and the Risk of Alzheimer Disease and Dementia in Elderly Men: A Prospective, Population-Based Cohort Study
Sundelof et al.
Arch Neurol 2008;65:256-263.
ABSTRACT
| FULL TEXT
|
